Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

» ABPI's 10-Y Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with ABPI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details

Accentia Biopharmaceuticals Inc is a bio pharmaceutical company focused on the development and commercialization of late-stage clinical products in the therapeutic areas of respiratory disease and oncology. The Company has two product candidates entering or in Phase III clinical trials. Their first product candidate, SinuNase, has been developed as a novel application and formulation of a known therapeutic to treat chronic rhinosinusitis which is a long-term inflammatory condition of the paranasal sinuses for which there is currently no FDA-approved therapy. They submitted an Investigational New Drug Application with the FDA for SinuNase in April 2005, and the Investigational New Drug Application was accepted by the FDA in May 2005. They expect to initiate Phase III trials for SinuNase later in calendar year 2005. Their second product candidate, Biovaxid, is a patient-specific cancer vaccine focusing on the treatment of follicular non-Hodgkin's lymphoma. Biovaxid is currently in a pivotal Phase III clinical trial under an Investigational New Drug Application that they acquired from the National Cancer Institute in 2004. In addition to these product candidates, the company is also involved in pharmaceutical business with a portfolio of ten currently marketed products and a pipeline of products under development by third parties. Their goal is to utilize their vertically integrated business structure to cost-effectively and efficiently develop and commercialize innovative therapeutics that addresses unmet medical needs.



Valuation & Return


More Statistics

Short Percentage of Float2.93%
52-Week Range $0.00 - 0.01
Shares Outstanding (Mil)89.76
» More Articles for ABPI


Articles On GuruFocus.com
No related article found.

More From Other Websites
No related articles found.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)